Springer Nature OAopen access
GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection
Medicine & Public Health, Internal Medicine, Metabolic Diseases, Human Physiology
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 319403
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.